Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 13, 2025, details the closing of a strategic acquisition and concurrent financing activities by Vivos Therapeutics, Inc. The primary event is the acquisition of The Sleep Center of Nevada (SCN), completed on June 10, 2025, effective June 2, 2025. The filing also discloses the execution of a senior secured loan and a private placement equity offering (PIPE) on June 9, 2025, to fund the transaction and support working capital.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: Total consideration for SCN includes $6.0 million in cash, 607,287 shares of restricted common stock valued at $1.5 million (based on 30-day VWAP), and the assumption of specific trade payables. A contingent "earn-out" of up to $1.5 million in restricted stock is possible upon achieving financial milestones.
- Debt Financing: The Company issued a Secured Promissory Note with a principal amount of $8,250,000. After an original issue discount of $675,000 and transaction costs of $50,000, the Company received gross proceeds of $7,500,000. The note bears 9% annual interest and matures in 18 months.
- Equity Financing (PIPE): The Company sold 828,000 shares of Common Stock, a pre-funded warrant for 725,258 shares, and a warrant for 2,329,886 shares to V-CoInvestors 2 LLC. The purchase price was $2.42 per unit. The Company received $2,655,000 in cash proceeds, plus $1,100,000 from the conversion of a prior bridge note, totaling $3,655,000 in gross proceeds.
- Operating Commitments: The Company's subsidiary, Airway Integrated Management Company (AIM), entered into Practice Administration Agreements (PAAs) with SCN entities, committing to pay monthly administration fees of $200,000 and $100,000 respectively. The Seller Principal has a new employment agreement with an annual base compensation of $400,000 plus potential bonuses.
Material Changes and Agreements
The filing represents a material expansion of the Company's footprint into Nevada sleep testing and treatment markets. Key structural changes include:
- Asset Acquisition: Vivos acquired all operating assets of SCN, including three leased facilities in Las Vegas and North Las Vegas.
- Debt Structure: The new debt is secured by all tangible and intangible assets of AIM and the Company's membership interests in AIM. It includes a redemption feature allowing the lender to redeem up to $550,000 per month starting six months post-issuance.
- Equity Dilution: The PIPE offering introduces new shares and warrants, with anti-dilution protections and beneficial ownership limitations (capped at 19.99%) for the investor.
- Management Integration: The Seller Principal retains a board observation right and is subject to exclusivity and non-compete clauses for the 15-year term of the PAAs plus one year post-termination.
Outlook, Risks, and Contingencies
Management intends to use the net proceeds from the debt and equity financings to fund the cash portion of the acquisition and support general working capital. The filing highlights several risks and contingencies:
- Financial Milestones: A portion of the acquisition consideration ($1.5 million) is contingent on SCN achieving specific financial targets.
- Debt Covenants and Penalties: The Note includes a prepayment premium of 107% if prepaid within 120 days of issuance. A one-time monitoring fee may be added to the principal if the note remains outstanding after 120 days. Default triggers include non-payment, bankruptcy, or failure to obtain consent for fundamental transactions.
- Regulatory Compliance: The transaction structure relies on compliance with Nevada corporate practice of medicine (CPM) laws, necessitating the PAAs and specific employment agreements.
- Registration Obligations: The Company must file a resale registration statement for the PIPE securities within 45 days and have it effective within 90 days.
Investor Verification Checklist
- Verify the fair market value of the $7.5 million cash consideration paid for SCN assets relative to the acquired revenue and EBITDA (financial statements to be filed within 71 days).
- Review the specific financial milestones required to trigger the $1.5 million earn-out payment.
- Assess the impact of the 9% interest rate and mandatory redemption provisions on the Company's future cash flow and liquidity.
- Confirm the status of the resale registration statement for the PIPE securities to ensure liquidity for the new investor.
- Examine the lease agreements for the three Nevada facilities to understand the duration and terms of the real estate commitments.